Sagility’s Outsourcing Tailwind

$SAGILITY Sagility is gaining from a clear structural shift: more U.S. hospitals are outsourcing work to India, and that can support steady revenue growth for the company. For shareholders, this is generally positive because the business is tied to a large, recurring demand trend rather than a one-off event. Sagility’s latest reported numbers show strong momentum. Revenue for FY25 was about ₹1,971 crore, up 16.58% year on year, while net profit rose to ₹355 crore, up 273.38%. In the June 2025 quarter, revenue was ₹479.61 crore and net profit was ₹96.73 crore, with net margin at 20.47%. Another recent quarter showed revenue of ₹14,166 million, adjusted EBITDA of ₹3,690 million, EBITDA margin of 26.1%, adjusted PAT of ₹2,015 million, and adjusted EPS of ₹0.43. For shareholders, the benefit is straightforward: if U.S. healthcare clients keep shifting work to lower-cost Indian vendors, Sagility can expand volume, improve margins, and increase earnings. That usually helps valuation if execution stays strong. But there are also risks. The company is heavily exposed to U.S. healthcare outsourcing, so any slowdown in client spending, contract losses, pricing pressure, or regulatory changes could hurt growth. The stock can also become expensive if the market prices in too much future optimism too early. Overall, the trend looks beneficial for Sagility shareholders because it gives the company a long runway for growth and margin expansion. Still, the stock remains dependent on execution, client concentration, and sustained outsourcing demand.